MedPath

Comparison of the Effects of Morton's Neuroma on Foot Pressure Distribution and Gait Parameters in Pes Planus and Pes Cavus Patients

Completed
Conditions
Morton Neuroma
Pes Planus
Pes Cavus
Interventions
Other: Comparison of gait and foot pressure
Registration Number
NCT05012488
Lead Sponsor
Acibadem University
Brief Summary

The aim of our study is to compare the effect of Morton's neuroma in feet with pes planus and pes cavus on foot pressure and temporal and spatial gait parameters.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
40
Inclusion Criteria
  • Patients diagnosed with bilateral pes planus or pes cavus

  • Diagnosis of unilateral Morton neuroma

  • Confirmation of the diagnosis of Morton's neuroma with Magnetic Resonance Imaging (MRI)

  • Pain level of the patients during walking is at least 3 according to the Visual Analogue Scale (VAS).

    • Volunteer to study over the age of 18
Exclusion Criteria
  • Having Symptomatic musculoskeletal disease in the lower extremity
  • Having peripheral nervous system disease
  • Presence of rigid deformity in the foot
  • Extremity or contralateral extremity surgery with Morton's neuroma
  • Having received physiotherapy in the last 3 months

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Morton Neuroma + pes cavusComparison of gait and foot pressureThe effect of unilateral morton neuroma on gait parameters and foot pressure distribution in patients with bilateral pes cavus will be investigated. Foot pressure distributions and gait parameters of the patients; foot rotation, step length, stance phase percentage, swing phase percentage, cadence, velocity, rerefoot pressure, midfoot pressure and forefoot pressure will be recorded with Zebris FDM -T ( Force distiribution Measurement Treadmill ) system. Zebris is a name of company in German .
Morton Neuroma + pes planusComparison of gait and foot pressureThe effect of unilateral morton neuroma on gait parameters and foot pressure distribution in patients with bilateral pes planus will be investigated. Foot pressure distributions and gait parameters of the patients; foot rotation, step length, stance phase percentage, swing phase percentage, cadence, velocity, rerefoot pressure, midfoot pressure and forefoot pressure will be recorded with Zebris FDM -T ( Force distiribution Measurement Treadmill ) system. Zebris is a name of company in German .
Primary Outcome Measures
NameTimeMethod
Swing phase percentage4 weeks

Swing phase percentage (%) will be evaluated by Zebris (Zebris Medical Limited -, Germany) FDM (Force distribution measurement ) System. Participants will walk barefoot on the Zebris FDM (Zebris Medical Limited, Germany) treadmill system. Swing phase describes the phase of a gait cycle during which the foot has no contact with the ground. The unit is expressed as a percentage.

Foot rotation4 weeks

Foot rotation (degree), will be evaluated by Zebris (Zebris Medical Limited - Germany) FDM (Force distribution measurement ) System. Participants will walk barefoot on the Zebris FDM (Zebris Medical Limited, Germany) treadmill system. Aim of the system to assessment the angle between the longitudinal axis of the foot and the running direction. Negative value = inward rotation, positive value = outward rotation.Subtalar joint supination describes angulation in the negative direction and pronation describes the angulation in the positive direction.Unit of measure is degrees.

Step length4 weeks

Step length (cm) will be evaluated by Zebris (Zebris Medical Limited -, Germany) FDM (Force distribution measurement ) System. Participants will walk barefoot on the Zebris FDM (Zebris Medical Limited, Germany) treadmill system. Aim of the system analyzes gait of the patients. Step length describes the distance between the heel contact of one side of the body and the heel contact of the contralateral side. Unit of measure is centimeter.

Cadance4weeks

Cadence (steps/min) will be evaluated by Zebris (Zebris Medical -Limited -, Germany) FDM (Force distribution measurement ) System. Participants will walk barefoot on the Zebris FDM (Zebris Medical Limited, Germany) treadmill system. Cadence is steps/minute. It is defined as the step frequency.

Velocity4 weeks

Velocity will be evaluated by Zebris (Zebris Medical -Limited -, Germany) FDM (Force distribution measurement ) System. Participants will walk barefoot on the Zebris FDM (Zebris Medical Limited, Germany) treadmill system. The system measures average gait speed during the analyzed measuring interval. The unit is expressed as km/hr.

Foot pressure distiribution4 weeks

Foot pressure distiribution will be evaluated by Zebris (Zebris Medical -Limited -, Germany) FDM (Force distribution measurement ) System. Participants will walk barefoot on the Zebris FDM (Zebris Medical Limited, Germany) treadmill system. The system evaluate the average maximum values reached in N/cm² for the three zones: toes, mid-foot and heel.

Stance phase percentage4 weeks

Stance phase percentage (%) will be evaluated by Zebris (Zebris Medical Limited -, Germany) FDM (Force distribution measurement ) System. Participants will walk barefoot on the Zebris FDM (Zebris Medical Limited, Germany) treadmill system. Stance phase percentage describes the phase of a gait cycle in which the foot has contact with the ground.The unit is expressed as a percentage.

Secondary Outcome Measures
NameTimeMethod
Demographic data/patient height4 weeks

The height of the patients will be recorded in the evaluation form in meters.

Demographic data/patient body mass index BMI4 weeks

The BMI of the patients will be recorded in the evaluation form in kg/m\^2

Demographic data/patient weight4 weeks

The weight of the patients will be recorded in the evaluation form in kilograms.

Demographic data/patient age4 weeks

The ages of the patients will be recorded in the evaluation form.

Trial Locations

Locations (1)

Fulya Foot Surgery Center

🇹🇷

Istanbul, Turkey

© Copyright 2025. All Rights Reserved by MedPath